Cite

HARVARD Citation

    Boyle, A. et al. (2020). Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. Journal of viral hepatitis. 27 (4), pp. 371-375. [Online]. 
  
Back to record